The BPaLM regimen promises a breakthrough in MDR-TB treatment with a shorter, all-oral approach. However, high costs, limited ...

Objective: To assess the efficacy, safety and tolerability of moxifloxacin, an 8-methoxy fluoroquinolone, in patients with respiratory tract infections (RTIs) treated in general practice in Germany.

An equitable TB programme is one where every individual receives the highest quality of person-centred care that takes into ...

India accounts for 30 per cent of the global TB burden and 62 per cent of multidrug-resistant cases. Despite a 17.7 per cent ...

The WHO report noted that five countries contributed to 56 percent of the worldwide TB cases—India (26 percent), Indonesia ...

Michael K. Jensen, B.S.Pharm., M.S., is Clinical Associate Professor of Pharmacy Practice, College of Pharmacy, University of Utah, Salt Lake City, and Clinical ...

Tuberculosis, an ongoing pandemic, highlights and exacerbates global disparities. With the prevailing model of standardised treatment in vertical health programmes, it is unsurprising that ...

Govt launches 826 drug-resistant centers under the 100-day TB-Mukt Bharat Abhiyan to combat tuberculosis. Get the latest ...

Paratek will accelerate access for XHANCE beyond specialists to primary care providers maximizing the recent label expansion for CRS in a ...